Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor

NCT03973918 is registered in ClinicalTrials.gov with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as lead sponsor.

NCT NCT03973918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03973918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase
Phase 2
Overall status
Terminated
Start date
July 29, 2019
Completion date
October 1, 2023
Enrollment
5 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic pleomorphic xanthoastrocytoma, braf v600e, braf v600k, glioblastoma, gliosarcoma, high grade glioma